Revolution Medicines Inc
RVMD46.200USD
-0.350-0.75%
收盤 09/15, 16:00（美東）報價延遲15分鐘
8.63B總市值
虧損本益比TTM
關於 Revolution Medicines Inc 公司
Revolution Medicines, Inc. 是一家臨牀階段的腫瘤學公司，致力於開發針對 RAS 成癮性癌症的新型靶向療法。該公司的研發管線包括直接與 RAS 變體結合的 RAS(ON) 抑制劑（稱爲 RAS(ON) 抑制劑）和針對 RAS 通路或相關通路中關鍵節點的 RAS 伴隨抑制劑（稱爲 RAS 伴隨抑制劑）。其 RAS(ON) 抑制劑旨在用作單一療法，與其他 RAS(ON) 抑制劑聯合使用和/或與 RAS 伴隨抑制劑或其他治療劑聯合使用。其 RAS 伴隨抑制劑主要用於以其 RAS(ON) 抑制劑爲中心的聯合治療策略。該公司的 RAS(ON) 抑制劑 RMC-6236 RMC-6291 和 RMC-9805 正在臨牀開發中。 RMC-6236 是其 RASMULTI(ON) 抑制劑，是一種強效、口服、RAS 選擇性三複合抑制劑，可抑制多種 RAS(ON) 變體，包括癌症驅動因素。
公司簡介
公司代碼RVMD
公司名稱Revolution Medicines Inc
上市日期Feb 13, 2020
CEODr. Mark A. Goldsmith, M.D., Ph.D.
員工數量534
證券類型Ordinary Share
年結日Feb 13
公司地址700 Saginaw Dr
城市REDWOOD CITY
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94063-4752
電話14157663638
網址https://www.revmed.com/
公司代碼RVMD
上市日期Feb 13, 2020
CEODr. Mark A. Goldsmith, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Wei Lin, M.D.
Dr. Wei Lin, M.D.
Chief Medical Officer
Chief Medical Officer
87.44K
-2.42%
Dr. Lorence H. Kim, M.D.
Dr. Lorence H. Kim, M.D.
Independent Director
Independent Director
67.09K
+4.91%
Ms. Margaret A. (Peg) Horn, J.D.
Ms. Margaret A. (Peg) Horn, J.D.
Chief Operating Officer
Chief Operating Officer
60.97K
-5.44%
Mr. Jeff Cislini
Mr. Jeff Cislini
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.49K
+48.70%
Mr. Jack Lee Anders, CPA
Mr. Jack Lee Anders, CPA
Chief Financial Officer
Chief Financial Officer
52.69K
--
Ms. Xiaolin Wang
Ms. Xiaolin Wang
Executive Vice President - Development
Executive Vice President - Development
48.39K
+87.73%
Dr. Flavia Borellini, Ph.D.
Dr. Flavia Borellini, Ph.D.
Independent Director
Independent Director
20.78K
+17.82%
Dr. Sushil Patel, Ph.D.
Dr. Sushil Patel, Ph.D.
Independent Director
Independent Director
17.09K
+22.52%
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth McKee Anderson
Ms. Elizabeth McKee Anderson
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Wei Lin, M.D.
Dr. Wei Lin, M.D.
Chief Medical Officer
Chief Medical Officer
87.44K
-2.42%
Dr. Lorence H. Kim, M.D.
Dr. Lorence H. Kim, M.D.
Independent Director
Independent Director
67.09K
+4.91%
Ms. Margaret A. (Peg) Horn, J.D.
Ms. Margaret A. (Peg) Horn, J.D.
Chief Operating Officer
Chief Operating Officer
60.97K
-5.44%
Mr. Jeff Cislini
Mr. Jeff Cislini
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.49K
+48.70%
Mr. Jack Lee Anders, CPA
Mr. Jack Lee Anders, CPA
Chief Financial Officer
Chief Financial Officer
52.69K
--
Ms. Xiaolin Wang
Ms. Xiaolin Wang
Executive Vice President - Development
Executive Vice President - Development
48.39K
+87.73%
收入明細
FY2024
FY2023
FY2022
FY2021
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8月15日 週五
更新時間: 8月15日 週五
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.41%
Farallon Capital Management, L.L.C.
7.66%
Janus Henderson Investors
5.67%
Wellington Management Company, LLP
5.49%
Baker Bros. Advisors LP
5.01%
其他
67.76%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.41%
Farallon Capital Management, L.L.C.
7.66%
Janus Henderson Investors
5.67%
Wellington Management Company, LLP
5.49%
Baker Bros. Advisors LP
5.01%
其他
67.76%
股東類型
持股股東
佔比
Investment Advisor
39.49%
Hedge Fund
31.59%
Investment Advisor/Hedge Fund
22.86%
Venture Capital
4.77%
Research Firm
2.52%
Individual Investor
2.03%
Sovereign Wealth Fund
0.91%
Private Equity
0.53%
Pension Fund
0.50%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
569
198.78M
106.34%
-10.16M
2025Q1
578
202.67M
108.85%
-6.24M
2024Q4
550
200.50M
107.86%
+9.16M
2024Q3
508
178.03M
106.09%
-11.19M
2024Q2
474
175.13M
105.71%
-4.08M
2024Q1
450
165.87M
97.52%
-10.22M
2023Q4
413
166.29M
101.77%
+33.45M
2023Q3
369
116.05M
106.21%
-8.60M
2023Q2
358
115.90M
109.17%
-5.53M
2023Q1
356
111.78M
105.38%
+16.81M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
16.58M
8.9%
-489.52K
-2.87%
Mar 31, 2025
Farallon Capital Management, L.L.C.
13.53M
7.27%
+286.00K
+2.16%
Mar 31, 2025
Janus Henderson Investors
10.19M
5.47%
+706.07K
+7.44%
Mar 31, 2025
Wellington Management Company, LLP
11.79M
6.33%
+966.23K
+8.93%
Mar 31, 2025
Baker Bros. Advisors LP
7.94M
4.26%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
7.41M
3.98%
+876.76K
+13.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
12.79M
6.86%
+151.14K
+1.20%
Mar 31, 2025
Nextech Invest, Ltd.
7.60M
4.08%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
6.18M
3.32%
-375.00K
-5.72%
Mar 31, 2025
BVF Partners L.P.
4.98M
2.67%
+801.21K
+19.16%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
3.72%
SPDR S&P Biotech ETF
1.48%
Direxion Daily S&P Biotech Bull 3X Shares
0.84%
iShares Biotechnology ETF
0.59%
Schwab U.S. Small-Cap ETF
0.18%
Schwab U.S. Mid-Cap ETF
0.15%
iShares Russell Mid-Cap Value ETF
0.07%
iShares Russell Mid-Cap ETF
0.05%
iShares Russell 1000 Value ETF
0.02%
iShares Russell 1000 ETF
0.01%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比3.72%
SPDR S&P Biotech ETF
佔比1.48%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.84%
iShares Biotechnology ETF
佔比0.59%
Schwab U.S. Small-Cap ETF
佔比0.18%
Schwab U.S. Mid-Cap ETF
佔比0.15%
iShares Russell Mid-Cap Value ETF
佔比0.07%
iShares Russell Mid-Cap ETF
佔比0.05%
iShares Russell 1000 Value ETF
佔比0.02%
iShares Russell 1000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
